Expanding drug-trafficking enforcement to counterfeit pharmaceuticals and substandard ingredients.

What it does

This bill amends the Fentanyl Sanctions Act to expand its scope beyond fentanyl to cover counterfeit drugs and 'copy-cat' pharmaceutical ingredients—substances designed to mimic approved drugs but made with inferior processes or lower purity. It allows the Director of National Intelligence to delegate authority to subordinates, adds a waiver permitting access to sanctioned medications during drug shortages, and makes conforming changes throughout the statute to reflect the broader focus on illicit drugs generally.

Why we flagged it

The bill's operative mechanism is to broaden existing sanctions authority from fentanyl-specific to all illicit drugs and counterfeit pharmaceuticals, adding definitional clarity and administrative delegation. It is a straightforward law-enforcement tool, not a market intervention or private carve-out.

What the text implies

• The 'copy-cat ingredient' definition may capture legitimate generic pharmaceutical manufacturing if the process differs from the original approval, creating potential enforcement ambiguity and compliance burden for generic manufacturers.
• The drug shortage waiver (Section 4) creates a narrow exception to sanctions but does not establish clear criteria for what constitutes a 'current drug shortage'—implementation will depend on HHS list maintenance and may leave gaps during supply disruptions.

The full analysis lists 3 implications of this text.

Who it affects

The bill expands law-enforcement tools against counterfeit and substandard pharmaceuticals that pose direct health risks to consumers, while adding a safety valve (drug shortage waiver) to prevent sanctions from blocking access to needed medications. The delegation provision is routine administrative efficiency.